CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses

Area of Science:

• Immunology
• Vaccine Development

Background:

• T cell responses depend on antigen targeting to specific receptors on dendritic cells (DCs).
• Different DC subsets and targeted receptors influence the quality and magnitude of T cell immunity.

Purpose of the Study:

• To investigate the efficacy of targeting model antigen ovalbumin (OVA) to various DC receptors (CD11c, CD205, MHC class II, CD40, TLR2, FcgammaRII/III).
• To determine the optimal DC targeting strategy for robust CD4 and CD8 T cell responses.

Main Methods:

• Utilized (Fab' x OVA) conjugates to target OVA to specific DC receptors.
• Performed in vitro studies for antigen presentation assessment.
• Conducted in vivo studies to evaluate T cell proliferation (OT-I and OT-II cells).
• Carried out biodistribution and immunohistochemical analyses.

Main Results:

• In vitro: CD11c, CD205, and MHC class II were effective immunotargets for antigen delivery.
• In vivo: Targeting antigen to CD11c demonstrated a significant advantage for both CD4 (OT-II) and CD8 (OT-I) T cell responses, even at low doses.
• Anti-CD205 and anti-MHC class II targeting resulted in substantially lower T cell proliferation.
• CD11c's efficient antigen capture in lymphoid tissues likely contributes to its superior T cell stimulation.

Conclusions:

• Targeting antigen to CD11c on dendritic cells is a highly effective strategy for promoting robust CD4 and CD8 T cell immunity.
• This approach offers a novel and potent strategy for vaccine development, distinct from other DC targeting methods.